NCT03370406View on ClinicalTrials.gov

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

September 30, 2026

Study Completion Date

October 30, 2026

Conditions
Carcinoma, Squamous Cell
Interventions
DRUG

5-fluorouracil

Intralesional injections of 50mg/ml over a 3 week period.

DRUG

Calcipotriene

Topical application of .005% cream two (2) times daily for four (4) days one (1) day after each of three (3) 5FU injections..

Trial Locations (1)

15238

RECRUITING

St. Margaret Hospital Dermatology, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Melissa Pugliano-Mauro

OTHER